文献速递药物不良反应与药物警戒

晚期黑色素瘤药物安全谱:基于FDA不良事件报告系统2008-2018年数据分析

Safety profile of drugs for advanced melanoma: A report based on 2008-2018 US Food and Drug Administration Data.
PubMed 文献 · Br J Clin Pharmacol · 2020-12-29

该研究基于美国FDA不良事件报告系统2008-2018年数据,描述了用于晚期黑色素瘤的化疗、免疫调节剂、靶向治疗和免疫治疗等所有药物类别在25 900例药物警戒病例中的不良反应。病例数随时间急剧增加,峰值与新疗法上市相关;不良反应谱随时间多样化,靶向治疗常关联皮肤和视网膜疾病,免疫治疗常关联内分泌疾病,还检测到神经精神障碍及胃肠道溃疡等较少见反应。

要点

  • 靶向治疗常报告皮肤(脱发、皮炎)和视网膜疾病。
  • 免疫治疗常报告内分泌疾病(下丘脑、甲状腺、肾上腺功能障碍)。
  • 靶向治疗可见神经精神障碍,免疫治疗可见胃肠道溃疡、气胸和胸腔积液。

核心结论

  • 晚期黑色素瘤各药物类别安全谱随时间多样化,需多专业医护人员加强并发症管理。

研究设计与样本

  • 基于美国FDA不良事件报告系统2008-2018年数据,描述25 900例药物警戒病例中晚期黑色素瘤所有药物类别的不良反应。

主要发现

  • 病例数随时间急剧增加,峰值与新疗法上市相关。
  • 皮肤(脱发、皮炎)和视网膜疾病频繁关联靶向治疗,内分泌疾病(下丘脑、甲状腺和肾上腺功能障碍)关联免疫治疗。
  • 检测到较少见反应:靶向治疗的神经精神障碍,免疫治疗的胃肠道溃疡、气胸和胸腔积液。

临床怎么用

  • 临床应关注靶向治疗的皮肤、视网膜及神经精神反应,以及免疫治疗的内分泌、胃肠道溃疡、气胸和胸腔积液等反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We describe the safety profiles of all drug classes used for the treatment of advanced melanoma from the US Food and Drug Administration Adverse Event Reporting System over 2008-2018. Adverse reactions reported in 25 900 pharmacovigilance cases are described for chemotherapies, immunomodulators, targeted therapies and immunotherapies. There was a sharp increase in the number of cases over time, with peaks associated with the launch of new treatments. The adverse reactions diversified over time; notably, skin (alopecias, dermatitis) and retinal disorders were frequently associated with targeted therapies and endocrine disorders (hypothalamus, thyroid and adrenal dysfunctions) with immunotherapies. Less well-known reactions were also detected, such as neuropsychiatric disorders with targeted therapies and gastrointestinal ulcers, pneumothorax and pleural effusions with immunotherapies. The findings highlight the need for various health professionals (including medical specialists or trained nurses) to enhance management of complications.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Casarotto E, Noize P, Létinier L, et al. Safety profile of drugs for advanced melanoma: A report based on 2008-2018 US Food and Drug Administration Data. Br J Clin Pharmacol. 2020. PMID: 33294983. doi:10.1111/bcp.14693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。